MDK and glioblastoma: All of the above-mentioned rationales may explain the lower survival rate and worse prognostic outcomes in the MDKhigh group, indicating that MDK plays a central role in GBM biology, and its inhibition might be a feasible strategy to increase the treatment efficacy of larger treatment regimens through inhibition of GBM cell proliferation and EMT as well as rebalancing of the tumor microenvironment.